Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 87

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 87
---
   At the taxonomic level Biomica's analysis allows strain-level resolution and relies on an extensive proprietary strain database.
------------------------------------------------------------------------------------------------------------------------------------

◾   At the functional level, Biomica's proprietary resources rely on a comprehensive catalog of microbial genes enabling mapping of an
                  average of 90% of the functions of the human gut microbiome obtained through metagenomics sequencing.               
--------------------------------------------------------------------------------------------------------------------------------------
 
In addition to its comprehensive computational solutions to profile the microbiome, Biomica also utilizes Evogene's ChemPass AI engine, for virtual screening of small molecular inhibitors to specifically target bacterial proteins of interest. This platform combines the physiochemical requirements for binding a specific protein target and utilizes a comprehensive proprietary database of over 20 billion known molecules for the discovery of potential therapeutics.
 
<{self.tag} alt="{self.alt}" src="{self.src}">Product Development Pipeline
  

Immune-Oncology
 
BMC128 is a rationally designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform powered by MicroBoost AI tech engine. Developed as a Live Bacterial Product, or LBP, BMC128 is an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbor specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes. Rationally-designed consortia are multi-strain products designed to restore diversity and specific functionality to a host's microbial community with individually selected, cultured bacteria.
 
On January 17, 2024, Biomica announced that the final patient has been enrolled in its Phase I clinical trial.
 
On May 23, 2024, Biomica announced initial findings from an ongoing Phase 1 clinical trial. In the study, Biomica is investigating the safety and tolerability of its microbiome-based immuno-oncology candidate, BMC128, in combination with nivolumab, an anti-PD1 immune checkpoint inhibitor, in patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma (RCC).
 
All eleven trial participants had experienced disease progression in prior immunotherapy treatment before joining the trial. These preliminary findings represent some of the initial positive evidence emerging from the burgeoning field of clinical research on cancer therapies leveraging gut microbiota.
 
Preliminary data from Biomica’s Phase 1 study of BMC128, in combination with ICI immunotherapy, in refractory patients, who previously progressed on immunotherapy